Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II DOX neoadjuvant chemotherapy study in advanced gastric cancer
ChiCTR1900022226Phase 2Recruiting
- Sponsor
- Sichuan Cancer Hospital
- Start
- Apr 2019
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of docetaxel, oxaliplatin and capecitabine in gastric cancer (GC) and gastroesophageal junction adenocarcinoma, sponsored by Sichuan Cancer Hospital. Primary endpoint: 3-year survival. Started Apr 2019; status: recruiting.
02
Drugs
docetaxeloxaliplatincapecitabine
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR1900022226.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900022226.